ABL Secures Two Major NIH Contracts to Accelerate Drug Development for Translational Sciences
August 29, 2024
| BioBuzz has been connecting the life science workforce since 2009. We’ve built an expansive community in the Mid-Atlantic with a national readership that spans from Massachusettes to Florida, and New York to California. For our next chapter, we’re building a proprietary talent logistics model to help employers source and hire life science talent. Learn more. |
In a significant boost to its role in advancing therapeutic biotechnology, Advanced BioScience Laboratories, Inc. (ABL) has been awarded two multi-year Indefinite Delivery, Indefinite Quantity (IDIQ) contracts from the National Institutes of Health (NIH), specifically the National Center for Advancing Translational Sciences (NCATS). These contracts allow ABL to contribute to the U.S. Government’s efforts to accelerate drug discovery and development, helping to address critical health challenges.
As part of these IDIQ contracts, ABL will provide NCATS with essential process and analytical development, as well as current Good Manufacturing Practice (cGMP) manufacturing services. These services are crucial for the translational development of biologic drug products, which include complex therapies like gene therapies, viral vaccines, and oncolytic viruses. ABL’s role in this partnership will involve accelerating critical biologic drug candidates from the discovery phase through to Investigational New Drug (IND) submission, a pivotal step in bringing new therapies to clinical trials.
Transforming Drug Development: A Strategic Partnership
The awarding of these contracts highlights ABL’s established expertise and its growing role in the biotechnology field. Lauren Hudacik, President and CEO of ABL, emphasized the importance of this collaboration, stating, “This award underscores our commitment to excellence in analytical development, process development, and GMP manufacturing. It allows the ABL team the inspiring opportunity to contribute to the future of drug discovery and development.”
For ABL, these contracts represent a continuation of its strategic partnership with NCATS and other government agencies. The collaboration will focus on advancing therapeutic biologics, a rapidly evolving area of biotechnology that holds promise for treating a wide range of diseases, including rare genetic disorders, cancers, and viral infections. By providing their manufacturing and development services, ABL will play a critical role in ensuring that promising drug candidates can move efficiently through the development pipeline, ultimately reaching patients in need more quickly.
The Broader Impact on Biotechnology and Public Health
The contracts with ABL are part of a broader effort by NCATS to transform the process of drug development, making it more efficient and effective. These contracts highlight the critical role that contract development and manufacturing organizations (CDMOs) like ABL play in the modern biotechnology landscape. As the demand for advanced biologic therapies continues to grow, the expertise and capabilities of CDMOs are increasingly essential to the success of drug development programs. ABL’s ability to meet stringent regulatory standards and provide high-quality manufacturing services positions it as a key player in this dynamic and rapidly evolving field.
About ABL
Advanced BioScience Laboratories, Inc. (ABL) is a contract development and manufacturing organization dedicated to advancing therapeutics, vaccines, and other biological products. With extensive experience working with industry, government, and academic entities, ABL provides comprehensive manufacturing capabilities for virus-based oncolytic therapies, gene therapies, and viral vaccines. The company’s services include bulk drug substance production, live virus fill/finish, and process and assay development, all conducted in facilities that meet U.S. regulatory standards.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
